Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data

por Lakota, Elizabeth A., Ong, Voon, Flanagan, Shawn, Rubino, Christopher M.
Publicado 2018

Traditional PK-PD Indices for Efficacy – Can We Do Better?

por Lakota, Elizabeth A, Bader, Justin C, Bhavnani, Sujata M, Andes, David R, Ambrose, Paul G
Publicado 2017

Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis

por Rubino, Christopher M, Smith, Larry R, Mammen, Mammen P, Hopkins, Andrew M, Lakota, Elizabeth A, Sullivan, Sean M
Publicado 2017

Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm

por Lakota, Elizabeth A., Landersdorfer, Cornelia B., Nation, Roger L., Li, Jian, Kaye, Keith S., Rao, Gauri G., Forrest, Alan
Publicado 2018

Time for Precision: A World Without Susceptibility Breakpoints

por Bader, Justin C, Lakota, Elizabeth A, Andes, David R, Rubino, Christopher M, Ambrose, Paul G, Bhavnani, Sujata M
Publicado 2018

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida

por Lakota, Elizabeth A, Ganesan, Harish, Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Bhavnani, Sujata M, Rubino, Christopher M, Ambrose, Paul G
Publicado 2018

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia

por Lakota, Elizabeth A, Friedrich, Lawrence, Steenbergen, Judith N, McGovern, Paul C, Tzanis, Evan, Bhavnani, Sujata M, Rubino, Christopher M
Publicado 2019

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

por Bader, Justin C., Lakota, Elizabeth A., Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Rubino, Christopher M., Bhavnani, Sujata M., Ambrose, Paul G.
Publicado 2018

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model

por VanScoy, Brian D., Lakota, Elizabeth A., Conde, Haley, McCauley, Jennifer, Friedrich, Lawrence, Steenbergen, Judith N., Ambrose, Paul G., Bhavnani, Sujata M.
Publicado 2020

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes

por Bulik, Catharine C, Bader, Justin C, Lakota, Elizabeth A, Bhavnani, Sujata M, Rubino, Christopher M, Sweeney, Kim L, Ambrose, Paul G, Owens, Robert C
Publicado 2017

1379. Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Mod...

por VanScoy, Brian D, Lakota, Elizabeth A, Bhavnani, Sujata M, Giesel, Greg, Carranco, Ana I, Nagira, Yu, Ouchi, Shohei, Kondo, Kenichiro, Ambrose, Paul G
Publicado 2018

Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems

por VanScoy, Brian D., Lakota, Elizabeth A., Conde, Haley, Fikes, Steven, Bhavnani, Sujata M., Elefante, Philippa B., Scangarella-Oman, Nicole E., Ambrose, Paul G.
Publicado 2021

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

por Lakota, Elizabeth A., Bader, Justin C., Ong, Voon, Bartizal, Ken, Miesel, Lynn, Andes, David R., Bhavnani, Sujata M., Rubino, Christopher M., Ambrose, Paul G., Lepak, Alexander J.
Publicado 2017

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection

por Bhavnani, Sujata M, Hammel, Jeffrey P, Lakota, Elizabeth A, VanScoy, Brian D, Nagira, Yu, Rubino, Christopher M, Sato, Nobuo, Koresawa, Tomokazu, Kondo, Kenichiro, Ambrose, Paul G
Publicado 2018

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

por Lakota, Elizabeth A., Van Wart, Scott A., Trang, Michael, Tzanis, Evan, Bhavnani, Sujata M., Safir, M. Courtney, Friedrich, Lawrence, Steenbergen, Judith N., Ambrose, Paul G., Rubino, Christopher M.
Publicado 2020

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising...

por Bhavnani, Sujata M., Hammel, Jeffrey P., Lakota, Elizabeth A., Trang, Michael, Bader, Justin C., Bulik, Catharine C., VanScoy, Brian D., Rubino, Christopher M., Huband, Michael D., Friedrich, Lawrence, Steenbergen, Judith N., Ambrose, Paul G.
Publicado 2023